key: cord-0829984-tiyhoj21
authors: Kricheldorf, Kim; Döhner, Konstanze; Stegelmann, Frank; Jost, Philipp J.; Lang, Fabian; Radsak, Markus; Hansen, Richard; Heuer, Vera; Röhrig, Rainer; Brümmendorf, Tim H.; Koschmieder, Steffen; Isfort, Susanne
title: Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: first results from a patient survey by the German Study Group for MPN
date: 2021-06-16
journal: Leuk Res
DOI: 10.1016/j.leukres.2021.106646
sha: 1f9a6274ab95675b0a574ade1d680cbd95dbaca5
doc_id: 829984
cord_uid: tiyhoj21

nan

Since 2020, the SARS-COV2 Coronavirus pandemic has spread worldwide, with a substantial impact on global health care systems. According to the World Health Organization (WHO) Coronavirus Dash Board, there were 1,053,869 cases of COVID-19 infections confirmed and 16 ,248 COVID-19-related deaths in Germany until data cut off on November 30 th 2020 [1] . Approximately 1.3 % of the German population had been infected with the virus in the first 10 months of the pandemic (with 83,190,556 inhabitants in Germany as reported by the Federal Statistical Office of Germany "Statistisches Bundesamt") [2] . As of data cut of in November 2020, 62,509,580 and 1,458,783 SARS-CoV-2 infections and COVID-19 related deaths were confirmed worldwide, respectively [3] .

Since the beginning of the pandemic, patient care in Germany has suffered considerably, either because patients were reluctant to personally see their physician due to fear of contraction of SARS-CoV-2 or because hospitals postponed scheduled interventions including surgery due to shortage of beds or personnel: according to a survey by the association of private insurance companies (Verband der Privaten Krankenversicherungen; PKV), 24% of patients with chronic diseases moved their appointments and the Deutsche Krankenhausinstitut (German hospital institute; DKI) reported that 41% of scheduled inpatient and 58% of out-patient surgical interventions were postponed.

The RWTH Aachen University Medical Center was one of the first hospitals in Europe to care for COVID-19 patients due to a local coronavirus breakout in early spring of 2020 [4] . We sought to capture the impact of COVID-19 on patients with myeloproliferative neoplasms (MPN) in Germany in order to better understand and address their needs. Therefore, we unexpected, given rates of 1.3% and 3.57 %, respectively, in the German population according to data published by the Robert Koch Institute [5] . These data suggest that the MPN patients participating in this survey were more successful in preventing a SARS-COV-2 infection than the general population. Even the patients´ relatives showed lower infection rates, as only 1% (n=4) of contact persons were tested positive for SARS-CoV-2. 99% of our patients used a medical mask ("mouth-nose protection") and 26% had undergone optional self-quarantine.

Asked about changes in medical care, our patients described that 30% of visits in outpatient care (routine MPN checkups) had been rescheduled. Of these visits, 39% have been rescheduled by the physician and 47% by the patient (13% indicated that their visits had been rescheduled but gave no further information). Among the patients with postponed appointments, only 30% had a consultation by phone instead.

In a second part of our survey, patients were asked if they had faced any problems in Only 10 (6%) out of 160 patients answering the question whether they had experienced challenges to receive their medication, reported problems: this included problems with the pharmacy (4%), problems to obtain a prescription (1%), or further unspecified problems (1%).

Patients with hematological malignancies seem to have an increased risk of a severe COVID-19 course and an increased need for hospitalization and intensive care compared to patients with other cancers [6] . Furthermore, Passamonti et al described an increased mortality rate of symptomatic COVID-19 patients with hematological malignancies, 41 times higher compared to a non-COVID-19-cohort with hematological malignancies and 4 times higher than in the J o u r n a l P r e -p r o o f general population with COVID-19 (without hematological malignancies), but the MPN disease itself was not predictive for a poor COVID-19 infection outcome [7] . Conversely, an European analysis demonstrated that mortality in MPN patients with COVID-19 was higher than in the general population and highest in MF patients [8] .

The German guidelines on treatment during COVID-19 pandemic recommend to make decisions on cancer treatment on an individual basis but to keep in mind, that a wellcontrolled therapy can affect infection courses positively [9] . In MPN patients, severe withdrawal syndromes, especially after ruxolitinib cessation, may occur [10, 11] and have been described to possibly worsen the COVID-19 course [8] . Therefore, currently, there is a general agreement (e.g. in the guidelines of the EHA infectious disease Scientific Working group [12] ) to continue therapy in MPN patients. According to our survey, the acceptance of these recommendations is quite high.

In case of a SARS-COV-2 infection in MPN patients, the decision on how to proceed with the ongoing medication becomes more complicated. Recent trials suggested that Janus-activated kinase (JAK) inhibitors such as ruxolitinib might treat SARS-CoV-2 induced systemic hyperinflammation [13] as the JAK/STAT pathway is linked to inflammatory processes [14] .

However, in the RUXCOVID trial (NCT 043621379), a phase III multicenter, randomized, double-blind, placebo-controlled 29-day study to evaluate the efficacy and safety of ruxolitinib plus standard of care (SoC) therapy compared to placebo plus SoC therapy in patients aged ≥12 years hospitalized for COVID-19 and not intubated or receiving ICU care prior to randomization, which enrolled 432 patients globally, the primary endpoint was not met (proportion of patients who died, or required mechanical ventilation due to respiratory failure or ICU care by Day 29) [15] . And it remains unclear if ruxolitinib or other immunosuppressive drugs increase the risk of developing COVID-19. MPN patients are at high risk of thromboembolic events [16] . Thrombembolic events have been described as one of the major complications during SARS-COV-2 infection leading to a worse outcome [17] [18]. In a recent analysis by Barbui et al, the essential thrombocythemia MPN subtype was associated with the greatest risk of venous thromboembolism during COVID-19 [19] .

Since none of our patients was affected by COVID-19, questions concerning their outcome remain to be answered in the next parts of this ongoing survey.

In summary, our patients successfully prevented infections with SARS-COV-2, but they did face challenges in their regular follow-up or, sometimes, in receiving their medication. The use of video-based teleconsultation or contact-free ways of getting a medical prescription may be a means to overcome these challenges. In contrast to countries with the geographical need J o u r n a l P r e -p r o o f to implement such methods in daily routine (such as Australia or India), the use of teleconsultation in Western Europe is still focused on specialized fields such as emergency medicine/stroke/myocardial infarction. As reported in a national online survey [20] , telemedicine was routinely used by only 19.6% of the medical staff in different health care settings in Germany (private practices or hospitals and university hospitals) [20] . Thus, better use of telemedicine may improve the care of MPN patients during the present and potential upcoming pandemics.

K. Kricheldorf and S. Isfort designed the study, collected data, analyzed the data, discussed the data, and wrote the manuscript. S. Koschmieder designed the study, collected data, discussed data, analyzed data and edited the manuscript. F. Stegelmann, R. Hansen, F. Lang, T.H. Brümmendorf, K. Döhner, P. Jost, M. Radsack and V. Heuer collected data and edited the manuscript. All authors approved the final version of the manuscript. 

World Health Organisation, WHO Coronavirus Disease (COVID-19) Dashboard -Germany

World Health Organisation, WHO Coronavirus Disease (COVID-19) Dashboard:, 2020

The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Clinical characteristics and risk factors associated with COVID-19 severity

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Coronavirus-Infektion (COVID-19) bei Patienten mit Blut-und Krebserkrankungen

Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Telemedicine in Germany During the COVID-19 Pandemic: Multi-Professional National Survey